SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’ Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR)
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.2932
https://www.valueinhealthjournal.com/article/S1098-3015(23)06063-1/fulltext
Title :
SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’ Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)06063-1&doi=10.1016/j.jval.2023.09.2932
First page :
Section Title :
Open access? :
No
Section Order :
12261